LEMS Therapy Access: Candidate Selection and NCCN Guideline Support

In "LEMS Therapy Access: Candidate Selection and NCCN Guideline Support," the panel explores who should be considered for LEMS-specific therapy and how to support access.

Dr. Iams opens by noting that a positive VGCC diagnostic test has largely driven authorization in his experience, and asks Dr. Patel who he considers a good candidate for amifampridine. Dr. Patel says essentially anyone with LEMS-related weakness not fully addressed by cancer treatment should be considered, whether treatment has already started or has not yet begun. On the access side, he emphasizes documenting both the antibody result and the weakness itself in the clinical note, calling it an obvious step worth stating explicitly since it directly supports authorization. Dr. Iams highlights that amifampridine is now integrated into the 2026 NCCN guidelines as the first LEMS-specific therapy for small cell lung cancer, and asks how oncologists should navigate that update relative to older, non-specific options. Dr. Patel says the guideline listing accomplishes two things. First, it reinforces awareness, helping clinicians remember LEMS exists and that testing for it matters. Second, having a treatment explicitly named in guidelines signals what peers recommend and helps secure insurance authorization, since many payers reference guideline inclusion when reviewing both cancer-specific and supportive care requests. Dr. Iams then asks about the ordering workflow itself, noting that his EMR lacks a formal treatment plan template for amifampridine the way it does for standard small cell regimens, making it feel more like an oral specialty pharmacy prescription with an up-titration schedule than a true infusional antineoplastic. Dr. Patel agrees, describing a similar process at his institution: the order is typed in directly and doses are adjusted much like a steroid taper for an autoimmune adverse event, rather than through a formal oncology treatment plan.

The next episode in this series, "How Group Purchasing Organizations Affect Access to LEMS Therapy," turns to a different access question: what role group purchasing organizations play in getting this therapy to patients.